Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate Plc (NYSE: CLVT) announced a reduction in its Board of Directors from 14 to 11 members, with the resignation of directors Balakrishnan S. Iyer, Kosty Gilis, and Roxane White. This move aims to enhance corporate governance, with 10 of the 11 remaining directors being independent and 45% being female or racially diverse. Board Chair Andrew Snyder emphasized that a smaller board will improve decision-making efficiency and focus on long-term growth and shareholder value.
Clarivate Plc (NYSE: CLVT) announced on December 6, 2022, the integration of linked specialty pharmacy claims data into its real-world data solutions. This new U.S. dataset enhances the company's offerings by providing insights into high-cost medications and the treatment journeys of patients with chronic and rare diseases. Specialty drugs comprise over 20% of the market in these areas. The dataset covers more than 500 specialty drugs and is updated weekly, enabling robust analytics and improved patient outcome strategies.
Clarivate Plc (NYSE: CLVT), a leader in providing insights to enhance innovation, announced that CEO Jonathan Gear and CFO Jonathan Collins will present at the Barclays Global Technology, Media, and Telecommunications Conference on December 7, 2022, at 10:25 AM PT (1:25 PM ET). Attendees can access the live webcast here, and it will be available for replay. Clarivate aims to assist customers in transforming innovations into real-world solutions.
Clarivate Plc (NYSE:CLVT) has launched its annual report, The Annual G20 Scorecard – Research Performance 2022, showcasing the research performance of G20 nations. Published by the Institute for Scientific Information, the report is timed with the G20 Summit in Bali. Key findings reveal that Australia maintains the highest international impact, while China's output has tripled. Saudi Arabia sees significant international collaboration, and South Korea leads in research expenditure. The UK and US demonstrate strong research impacts, with a notable focus on domestic and collaborative work.
On November 16, 2022, Clarivate Plc (NYSE: CLVT) announced a strategic partnership with IPwe Inc. to lead the digital transformation of intellectual property through advanced blockchain technology and AI. This collaboration aims to combine Clarivate's patent data with IPwe's Smart Intangible Asset Management platform, enhancing the validation and management of patent portfolios. By tokenizing patents, IPwe seeks to improve transparency and reduce transaction friction in the IP market. This partnership is expected to provide customers with a data-driven approach to managing intangible assets.
Clarivate Plc (NYSE: CLVT) announced the 2022 list of Highly Cited Researchers, recognizing 6,938 researchers worldwide for significant contributions across various fields. The U.S. leads with 2,764 researchers but has seen a gradual decrease in share since 2018. Mainland China is rapidly closing the gap, now with 1,169 researchers. Clarivate has enhanced its analysis to prevent research misconduct, ensuring the list reflects genuine influence. Notable findings include 7,225 total awards across disciplines, highlighting the global diversity of research excellence.
On November 9, 2022, Clarivate Plc (NYSE: CLVT) announced that CEO Jonathan Gear and CFO Jonathan Collins will present at the RBC Capital Markets 2022 Technology, Internet, Media and Telecommunications Conference on November 15, 2022, at 1:25 PM Eastern Time. A live webcast of the presentation will be available here and can be replayed later. Clarivate specializes in information and insights to expedite innovation across various sectors.
On November 8, 2022, Clarivate Plc (NYSE: CLVT; CLVT PR A) declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares. This dividend is payable in cash on December 1, 2022 to shareholders recorded as of the close of business on November 15, 2022. Clarivate continues to affirm its commitment to delivering value to its shareholders through consistent dividend payments.
Clarivate reported Q3 2022 revenues of $635.7 million, marking a 43.8% increase, driven by the acquisition of ProQuest. However, a significant non-cash goodwill impairment led to a net loss of $4,434.4 million, with a net loss per share of $6.64. Organic revenue growth was 1.2%, with subscription revenues rising 65.6%, but transactional revenues declined 9.4%. Adjusted net income was $143.7 million, up 26.5%. The company generated $372.4 million in cash from operations.
Clarivate Plc (NYSE: CLVT) announced a settlement with OCLC regarding allegations of misconduct, which Clarivate firmly denies. The agreement emphasizes the importance of collaborative platforms for bibliographic records, with Clarivate agreeing to not develop a MARC records exchange system that conflicts with OCLC's policies. This settlement is aimed at supporting the goals of open research and data exchange, facilitating a more efficient research process. Clarivate will cover its own legal fees related to this settlement.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
